Discrepancy in synaptic structural plasticity is one of the earliest manifestations of the neurodegenerative state. In prion diseases, a reduction in synapses and dendritic spine densities is observed during preclinical disease in neurons of the cortex and hippocampus. The underlying molecular mechanisms of these alterations have not been identified but microRNAs (miRNAs), many of which are enriched at the synapse, likely regulate local protein synthesis in rapid response to stressors such as replicating prions. MiRNAs are therefore candidate regulators of these early neurodegenerative changes and may provide clues as to the molecular pathways involved. We therefore determined changes in mature miRNA abundance within synaptoneurosomes isolated from prion-infected, as compared to mock-infected animals, at asymptomatic and symptomatic stages of disease. During preclinical disease, miRNAs that are enriched in neurons including miR-124a-3p, miR-136-5p and miR-376a-3p were elevated. At later stages of disease we found increases in miRNAs that have previously been identified as deregulated in brain tissues of prion infected mice, as well as in Alzheimer's disease (AD) models. These include miR-146a-5p, miR-142-3p, miR-143-3p, miR-145a-5p, miR-451a, miR-let-7b, miR-320 and miR-150-5p. A number of miRNAs also decreased in abundance during clinical disease. These included almost all members of the related miR-200 family (miR-200a-3p, miR-200b-3p, miR-200c-3p, miR-141-3p, and miR-429-3p) and the 182 cluster (miR-182-5p and miR-183-5p). Crown
Introduction
Neurodegenerative diseases are invariably incurable and are characterized by progressive structural and functional damage ultimately leading to the death of neurons in the brain. Prion diseases belong to this group and include human Creutzfeldt-Jakob disease, which occurs sporadically or genetically at a low rate in the population (Prusiner, 1998) . However, despite being rare and uniquely infectious, prion diseases share many common features on a sub-cellular level with other neurodegenerative diseases that are much more prevalent in the population, such as Alzheimer's disease (AD). The most obvious similarity is the strong association involving the accumulation of misfolded and insoluble forms of normal host proteins in the brains of patients. In prion diseases this protein is cellular prion protein (PrP C ), a GPI linked protein enriched in lipid rafts that refolds into a β-sheet-rich aggregated infectious form termed PrP Sc . Synaptic loss and dysfunction have been identified in animal models of both prion disease and AD, and correlate with cognitive decline prior to the manifestation of overt clinical signs. During the preclinical stage, up to 25% of synaptic density is reduced, which rises to 55% by terminal stages (Clinton et al., 1993; Kitamoto et al., 1992; Scheff and Price, 2006; Scheff et al., 2007; Siskova et al., 2009) . Recently, reversal of synaptic pathology was achieved in early stages of mouse prion disease suggesting that synaptic regeneration and recovery of neuronal function is possible (Mallucci et al., 2007; Moreno et al., 2013) . The mechanisms that underlie the morphological alterations of synaptic boutons and dendrite densities observed during prion disease are poorly understood. However, chronic N-methyl-D-aspartate (NMDA) receptor activity that is potentially modulated by PrP C leading to cytotoxic calcium overload Molecular and Cellular Neuroscience 71 (2016) 13-24 and neuronal damage, has been proposed as one possible mechanism (Khosravani et al., 2008) . At the molecular level, a gene expression signature indicative of synaptic NMDA-receptor signaling and calcium influx mediated transcription was identified in CA1 hippocampal neurons early in disease (Majer et al., 2012) . MicroRNAs (miRNAs) are important post-transcriptional regulators of gene expression that are implicated in numerous biological and pathological processes including neurodegenerative diseases (Szafranski et al., 2015) . Studies have found that specific miRNAs, their precursors, and protein components of the miRNA-mediated silencing complex (miRISC) are found in neuronal dendrites and are enriched in synaptic fractions (Lugli et al., 2012) . The mRNA/miRNA interaction fulfills the requirement to provide simultaneous flexibility and stability to synapses, bypassing a requirement for transcriptional control mediated from the cell nucleus. Although it remains to be shown that pri-and/or premiRNAs are converted to mature miRNAs within dendritic spines, localized processing in response to signals arising at individual synapses is certainly plausible (Lugli et al., 2012) . Indeed, both specific and global approaches have shown miRNAs to be involved in synaptic plasticity (Storchel et al., 2015) . MiRNAs can function in a synaptic activitydependent manner and participate in the regulation of synaptic plasticity (Siegel et al., 2011; Saba et al., 2012a; Joilin et al., 2014; Wibrand et al., 2012; Li et al., 2015; Most et al., 2016) . In some cases, they silence synapses by inhibiting expression of structural proteins or they may favor synaptic potentiation. Moreover, some miRNAs are primarily involved in maintaining homeostasis at the synapse by limiting the overexpression of synaptic proteins upon activation (Cohen et al., 2011; Fiore et al., 2014) .
Very few studies have identified how the miRNA complement of synaptic fractions changes during diseases and disorders. Fractions containing intact synaptoneurosomes typically possess the postsynaptic density, presynaptic vesicles and an intact mitochondrion. Given that changes in dendritic complexity occurs in the hippocampus and cortex during the entire course of prion disease, these changes are likely accompanied by alterations in miRNA abundances. Determination of these changes and how they might contribute to dendrite injury or synaptic plasticity during prion-induced neurodegeneration has not yet been studied.
Herein, we sought to investigate whether miRNA expression changes in synaptoneurosomes prepared from forebrains and hippocampi of mice at two time points during prion disease. The first is during the preclinical stage of disease when dendrite loss is initially discernible and gliosis and prion aggregates can be detected in the brain but no clinical signs are observed. The second is at the clinical endpoint of disease, when significant dendrite and neuronal loss is evident and accompanied by extensive prion accumulation, gliosis and vacuolation. We found differing abundances of small groups of miRNAs in the synaptoneurosomes collected at these two time points. During preclinical disease, miRNAs that are enriched in neurons including miR-124a-3p, miR-136-5p and miR-376a-3p, were elevated. At later stages of disease we saw increases in miRNAs that have previously been determined as deregulated in brain tissues of prion infected mice as well as AD models. These include miRlet 7b, . A number of miRNAs also decreased in abundance during clinical disease. These included almost all members of the related miR-200 family (miR-200a-3p, miR-200b-3p, miR-141-3p, and miR-429) and the miR-182 cluster (miR-182-5p and miR-183-5p) . Many of the identified miRNAs target important proteins that mediate structural morphology and function of synapses.
Results

Synaptoneurosome preparation
Synaptoneurosomes were prepared using methodology first described by Rao and Steward in 1991 and outlined in Supplementary   Fig. 1 (Rao and Steward, 1991) . We confirmed that the resultant fraction is enriched in axon terminals with adherent postsynaptic densities by electron microscopy and Western blotting, Supplementary Fig. 1 . We also showed that the small brain specific RNA BC1, which is known to be specifically transported into the dendritic processes of neurons, was also enriched (Supplementary Fig. 1 ) (Muslimov et al., 1997) . To further determine the efficacy of our methodology we prepared synaptoneurosomes from 3 independent wild-type mouse brains to ensure consistency and also to compare the miRNA complement with previously published data. Hybridization of total RNA to a high-density miRNA microarray consistently detected 97 miRNAs representing 73-96% of the total miRNAs from the 3 samples. In addition, 27 out of 31 miRNAs designated to be universally present in this fraction by Garza-Manero in 2014, were always amongst those detected (Supplementary Table 1 ), affirming the protocols we used were robust (GarzaManero et al., 2014) .
MiRNA expression was altered in synaptoneurosomes from prioninfected forebrain
It has previously been shown that qRT-PCR is considerably more sensitive than microarray technology for the detection of miRNAs (Jensen et al., 2011) , therefore we used Exiqon qRT-PCR platform for the remaining experiments. RNA was isolated from synaptoneurosomes prepared from RML and mock-infected mouse forebrains at two timepoints: 105 days post infection (dpi) -preclinical and 167 dpi (clinical end-point). A total of 372 rodent miRNAs, plus controls, were assayed using the Exiqon qRT-PCR panel I. Almost three-quarters (281 of 372) of the rodent miRNAs assayed met our cut-off criterion for detection of a Ct value b 35 (Supplementary Table 2 ). This included all 97 of the miRNAs previously detected by microarray analysis.
Data was subsequently processed and analyzed using GenEx Enterprise v.6 software. Briefly, the data was pre-processed and normalized to correct for inter-plate variability, and a two-tailed t-test was performed to determine miRNAs with statistically altered abundances between infected and control mice (p-value ≤ 0.05 and a relative fold-change ≥ 1.75). The data for the 105 dpi and 167 dpi samples is displayed as Volcano plots in Fig. 1 . The majority of miRNAs were extremely consistent in abundance between all the samples analyzed. In total, 9 probes showed a significant increase in abundance at 105 dpi, however, for miR-136-5p and miR-345-5p, both the mouse and rat probes were similarly identified, therefore the data actually corresponds to 7 unique miRNAs; miR-136-5p, miR-361-5p, miR-212-3p, miR-129-2-3p, miR-345-5p and miR-124-3p . None of these miRNAs have a reported association with prion disease except miR-124-3p which we have previously shown to be upregulated in neuronal cell bodies during preclinical disease (Majer et al., 2012) . No miRNAs decreased in abundance met the significance threshold.
At terminal disease, 13 miRNAs increased in abundance while 12 were decreased. Five of these, miR-146a-5p, miR-142-3p, miR-143-3p, miR-150-5p and miR-451a were previously increased at terminal stage of prion disease (Majer et al., 2012; Saba et al., 2008; Montag et al., 2009) . Numerous other miRNAs that met the p-value criteria of less than 0.05 (but had less than the 1.75-fold threshold fold-change) have also been reported to have altered abundance in prion-infected animals (Majer et al., 2012; Saba et al., 2008; Montag et al., 2009 Montag et al., , 2012 . Given this association, we have listed all those miRNAs with a relative fold change ≥ 1.4 in Table 1 . These include miR-544-3p, miR-7b, miR-145a-5p, miR-134-5p, miR-129-2-3p, miR-let-7b-5p, miR-let-7c-5p, miR-433-3p, miR-9-3p (p-value ≤ 0.05; FC ≥ 1.4). We also note that a number of these miRNAs are highly likely to be co-transcribed as they are encoded on the same chromosome at adjacent sites.
Temporal miRNA deregulation in synaptoneurosomes from forebrain during prion disease
The miRNA complement differed markedly between early and late prion disease with little overlap between the two temporal groups. However, miR-376a-3p, miR-361-5p, miR-136-5p and miR-129-2-3p, identified during early disease, all showed marginal alterations in abundance (p-value b 0.05; FC ≥ 1.4). Whilst miR-136-5p and miR-376a-3p still showed a slight increase in abundance, miR-361-5p and miR-129-2-3p conversely showed a slight decrease in abundance during terminal disease (Table 1) . We previously found a similar phenomenon whereby discrete patterns of deregulated transcripts are evident in early versus later stages of disease in pyramidal neurons microdissected from the CA1 hippocampal region of prion-infected mice (Majer et al., 2012) . The current data supports our hypothesis that different regulatory circuits govern the synaptodendritic-compartments at different temporal stages of disease.
MiRNA deregulation in hippocampal synaptoneurosomes during early prion disease
Given that our previous work identified temporal changes in the abundance of miRNAs specifically from cell bodies of CA1 hippocampal neurons, we were particularly interested to determine alterations in miRNA abundance in synaptoneurosomes prepared from the hippocampus. Due to the small size of a mouse hippocampus it was not possible to isolate synaptoneurosomes from single hippocampi for miRNA analysis. We therefore pooled 8 hippocampi from infected, and an equal number from age-matched mock-infected mice, fractionated the synaptoneurosomes and used the extracted RNA for miRNA profiling. Analysis between RML-infected versus mock-infected samples revealed that 19 were upregulated while 21 miRNAs were downregulated at preclinical prion disease (Fig. 2) .
Validation of miRNAs expression at early and terminal stages of disease
Several miRNAs were validated by TaqMan qRT-PCR (Table 2 ). Normalization was relative to the small RNA U6. This independent assay confirmed the relative abundances of the miRNAs tested in the samples collected from the mouse forebrains during clinical disease at 167 dpi. Forebrain samples collected at 105 dpi showed greater sample-tosample variation, as we expected considering the relatively early stage of disease when alterations in synaptic plasticity are subtle. However, a number of miRNAs were confirmed to have statistically significant, albeit modest, changes in expression. A number of these, including miR-136-5p and miR-376a-3p increased more than 2-fold in pooled hippocampal synaptoneurosomes as well as in forebrain samples collected during clinical disease. We concluded that the dataset is highly reproducible given the trend in miRNA expression was confirmed by different methodologies and in samples from tissue taken from different MiRNA expression was altered in synaptoneurosomes from prion-infected forebrain. Volcano plots depicting changes in miRNA expression at (A) 105 dpi and (B) 167 dpi between prion infected and mock-infected forebrains (n = 8 at dpi 105; n = 6 at dpi 167). The negative log 10 -transformed p-values of the two-tailed Student's t-test are plotted against the log fold change. The horizontal line represents the designated significance level (p-value ≤ 0.05) for miRNAs with statistically altered abundances between infected and control mice. The vertical dashed bars denote (A) ≤ 1.75-fold decrease or (B) ≥ 1.75-fold increase in abundance of miRNAs identified in synaptoneurosomes from infected mice as compared to controls. MiRNAs not altered between prion-infected and control samples are highlighted in gray. Bar graphs represent relative quantification levels for miRNAs deregulated at (C) 105 dpi and (D) 167 dpi. biological experiments. Significant down-regulation of most members of the miR-182 cluster (miR-182-5p and miR-183-5p) and the two clusters that comprise the miR-200 family (miR-200a-3p, miR-200b-3p, miR-141-3p , and miR-429) was found at disease endpoint and in hippocampal synaptoneurosomes early in disease. Validation of the levels of miR-200c-3p, and miR-141-3p in endpoint samples, plus miR-183-5p in hippocampal synaptoneurosomes, confirmed this trend. In fact, miR-200c-3p and miR-141-3p were also shown to be downregulated by approximately 3-fold in the early forebrain samples based on TaqMan qRT-PCR.
Synaptoneurosome fractions from RML-infected mice are not contaminated with activated glia
Two miRNAs that increased in abundance in synaptoneurosomes collected at terminal disease, miR-146a-5p and miR-142-3p, have previously been ascribed functions related to regulation of the innate immune system (Saba et al., 2012b; Taganov et al., 2006) . Activation of glia is concomitant with prion replication in infected mouse brain and we considered whether the altered abundance of some miRNAs by terminal disease could be the result of progressive contamination of material from activated glia, rather than altered functionality at the neuronal synapse. Therefore we performed a Western Blot to determine whether GFAP, a marker of activated glia, co-purified with the synaptoneurosome preparation. We detected GFAP at each step of the preparation, however, there was a dramatic decrease (N90%) in the quantity relative to α-tubulin in the synaptoneurosome-enriched fraction (Fig. 3A) . The relative quantities of GFAP in comparison to α-tubulin in mock-infected and RML infected mice at early and terminal disease were assessed in forebrain and hippocampal synaptoneurosome preparations. The ratio of GFAP/α-tubulin remained the same in forebrain of mock-infected and infected mice at both early and terminal disease ( Fig. 3B -C, E-F) while a slight increase in GFAP was detected in hippocampal preparations from prion-infected animals ( Fig. 3D) . We also observed a significant decrease in relative amount of PSD-95 in the forebrain of prion-infected animals at terminal disease ( Fig. 3E and F) indicative of synaptic loss. Collectively, this data suggests that the 4-7 fold increase of miR-146a-5p and miR-142-3p in synaptoneurosomes at terminal disease was unlikely to originate from activated glia, but was rather due to alterations in the abundance of these miRNAs in the synaptodendritic compartment.
Bioinformatic prediction of the combinatorial effect of altered miRNA abundance in the synapto-dendritic compartment during disease
To predict potential targets that are co-localized with miRNAs dysregulated during disease, and also to potentially draw inferences about their regulatory capacity by miRNAs, we limited our analysis to proteins that are detected in synaptoneurosomes by mass spectrometry. By compiling data from four different forebrain preparations from adult CD1 mice, and excluding proteins that were not identified in at least two preparations, we assembled a list of 2147 proteins, of which 1636 individual proteins were annotated by the IPA bioinformatics tool (Supplementary Table 3 ). Enrichment of proteins known to be located in the post-synaptic density, synaptic vesicles and mitochondria was clear (Supplementary Table 4 ). The canonical pathways represented by these proteins were also highly enriched for neuronal functions. The protein complement was very similar to other published studies that determined the synaptoneurosome proteome (Distler et al., 2014) .
Using this list, and the DIANA-miRPath v2.0 online tool, we determined the predicted targets of all miRNAs either over-or underrepresented at either the preclinical or clinical endpoint that are also detected within the protein complement of synaptoneurosomes prepared from adult mice. The biological effect of miRNA dysregulation within the synaptoneurosome was assessed by identifying KEGG curated pathways significantly enriched in predicted miRNA targets (Paraskevopoulou et al., 2013; Reczko et al., 2012) . Data was corrected for multiple hypotheses testing by application of the Benjamini and Hochberg FDR. The top 10 most enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways for the preclinical and late timepoints for miRNAs isolated from forebrain and hippocampus are provided in Table 3 .
As miRNAs altered in abundance in infected forebrain and hippocampal samples had some degree of consensus, it is not surprising that the top 10 KEGG pathways are similar. Interestingly the pathway highlighted as significant with p-values of 4.0 × 10 −28 (late forebrain) and 1.9 × 10 −28 (hippocampus) was the KEGG pathway for prion diseases. In the forebrain samples 11 miRNAs altered in abundance target 6 genes in the prion disease KEGG pathway (PRNP, LAMC1, FYN, MAPK1, MAP2K1, HSPA5), while 12 miRNAs similarly target 7 pathway genes (6 mentioned previously plus NCAM1), amongst the hippocampal miRNAs tested (4 of these miRNAs were identified in common in between forebrain and hippocampal synaptoneurosomes). Other pathways predicted to be significantly targeted by the combination of altered miRNAs are those of axon guidance, long-term depression and potentiation, regulation of the actin cytoskeleton, various synapse-related pathways and pathways involved in endocytosis and synaptic vesicle production. A number of other neurodegenerative disease pathways were also predicted, such as those for AD and amyotrophic lateral sclerosis (ALS), although the p-values calculated are much less significant, ≥10 −5
. Given that the potential targets were selected from a small pool of genes from a highly specific tissue, we also tested for bias by picking 10-15 miRNAs at random from the pool of those that are detected in the synaptoneurosomes, and performing a similar analysis with the mirPath v2.0 tool. On 10-20 occasions we found that the predicted targets of randomly selected miRNAs were enriched in KEGG pathways with much lower calculated significant values; generally p-values N 10 . Therefore we concluded that the significance values assigned by the software for the predicted targets of experimentally identified miRNAs during disease represented true functional enrichment.
In Fig. 4 we show an interaction network generated by the Ingenuity Pathway Analysis tool (IPA) showing the members of the synaptoneurosome proteome that are potentially direct targets of miRNAs that changed in abundance in synaptoneurosome preparations from the forebrain tissue. Potential targets of miRNAs altered either during early or late disease, are shown. The "fill intensity" represents the predicted number of binding sites in the 3′UTRs of proteins detected in the synaptoneurosome fraction by mass spectrometry. No fill represents a lack of predicted binding sites whereas the most intense black fill represents the maximum of 8 binding sites. 
Materials and methods
Ethics statement
All procedures involving live animals were approved by the Canadian Science Centre for Human and Animal Health-Animal Care Committee (CSCHAH-ACC) according to the guidelines set forth by the Canadian Council on Animal Care. All protocols were specifically designed to minimize animal discomfort. The approval identification for this study is the animal use document (AUD) #H-11-020.
Prion inoculation and sample collection
CD1 mice between 4 and 6 weeks of age were inoculated intraperitoneally with 200 μL of 2% brain homogenate in PBS: mock-infected animals (control), were injected with brain homogenate from wildtype mice whilst RML infected animals were injected with brain homogenate from RML scrapie-infected mice at the terminal stage of disease. Animals were sacrificed and whole brains from 8 mice per treatment group were collected on ice at 105 dpi, representing preclinical disease, and mice at 167 dpi representing terminal disease. Clinical signs used to delineate terminal disease were kyphosis, dull ruffled coat, weight loss of 20% or more and ataxia.
Synaptoneurosome preparation
Synaptoneurosomes were prepared from macro-dissected forebrain and hippocampus structures as previously described (Rao and Steward, 1991) . Briefly, tissue was immersed in 50 mL of homogenization buffer (0.32 M sucrose, 0.1 mM EDTA, 0.25 mM DTT, 2 mM HEPES, Fig. 3 . Synaptoneurosomes isolated from brain tissue are not contaminated with activated glia during prion disease. (A) Representative Western blot analysis showing the relative expression of GFAP to α-tubulin in the total cell lysate (Lys) and soluble fractions S1 and S2 that are produced during the synaptoneurosome preparation as described in the schematic provided in Supplementary Fig. S1 . Western blot analysis of synaptoneurosome preparations from 3 mock-infected (control) and 3 RML infected mouse forebrains collected at 105 dpi are provided in (B) and (C) showing that the relative amounts of the postsynaptic density marker, PSD95, and astrocytic marker GFAP, remain similar in prion infected and control mice. Panels (B) and (D) are Western blots showing that PSD95 and GFAP levels in the pooled hippocampal synaptoneurosome samples collected at the same time post infection also remain unchanged relative to α-tubulin. Panels (E) and (F) show Western blot analysis of synaptoneurosome preparations from 4 mock-and 4 RML-infected mice during clinical disease. We show that although the relative expression of GFAP remains the same relative to α-tubulin, the amount of PSD95 decreases significantly (p b 0.01) in the infected mice. pH 7.4) and disrupted by 8 strokes in a Teflon-coated Dounce-Potter homogenizer (Wheaton). Nuclei and cell debris were pelleted by centrifugation for 2 min at 2000 ×g. The supernatant was centrifuged for an additional 10 min at 14,000 ×g and the resulting pellet represented a crude synaptoneurosome containing fraction. The fraction was subsequently layered over a 5-13% discontinuous Ficoll gradient that had been equilibrated at 4°C for 1 h. Synaptoneurosomes were collected from the gradient interface after centrifugation at 45,000 ×g for 45 min at 4°C.
Total RNA and protein extraction
Half (600 μL) of the synaptoneurosome layer was used for RNA extraction with the mirVana Isolation Kit (Ambion), while the other 600 μL was placed in cell disruption buffer (nonionic detergent from mirVana Paris kit, Ambion) for protein analysis.
RNA extraction was performed according to the mirVana Isolation kit standard protocol, which involves a phenol:chloroform extraction followed by on-column isolation. RNA was checked for quality and quantity using the Bioanalyzer 2100 and RNA 6000 Pico chip (Agilent).
MiRNA profiling by Agilent microarrays and Exiqon miRNA PCR panels
Agilent's miRNA microarrays were performed using Agilent's standard protocol. 100 ng of total RNA was dephosphorylated with calf intestine alkaline phosphatase, denatured with dimethyl sulfoxide, and 3′ end-labeled with pCp-Cy3. The labeled RNAs were dried and hybridized using Agilents Microarray System labeling kit and rodent arrays for 20 h at 55°C. After hybridization and washing, the arrays were scanned with an Agilent microarray scanner. A signal intensity over 100 units in 3 out of 3 independently prepared replicates was used as the criteria to identify whether a particular miRNA was present.
Alternatively, the miRCURY LNA Universal RT microRNA PCR kit (Exiqon) was used to produce cDNA. The resulting cDNA was used for analysis using the microRNA Ready-to-Use PCR Mouse panel I V2.0 M (Exiqon Inc.). A mixture of 2000 μL of 2 × SYBR Green Master mix, 1980 μL water and 20 μL cDNA was prepared and 10 μL of this mix was added to each well of the 384 well panels. The plate was sealed and centrifuged at 1500 ×g for 1 min. The qPCR was performed on the ViiA 7 thermocycler under the following conditions: 95°C for 10 min followed by 40 amplification cycles of 95°C for 10 s, 60°C for 1 min with a ramprate of 1.6°C/s, relating to the standard ramp rate on this instrument, followed by melting curve analysis. An automatic threshold was applied using ViiA 7 RUO software and the resulting Cts were used for analysis, with melting curves examined to ensure single PCR products.
Data analyses
GenEx 6.2 Enterprise software (MultiD Analyses AB, Göteborg, Sweden) was used to analyze the data from the Exiqon PCR panel data. MiRNA expression levels were calculated using the ΔΔCq method with global normalization (Livak and Schmittgen, 2001; Mestdagh et al., 2009) . Briefly, interplate and spike-in calibrations were performed as per the GeneEx which was followed by removal of samples with Cq N 39 and miRNAs that were not detected in all of the samples. Global normalization of Cq values was performed using the mean of all samples. Relative quantities of each miRNA were calculated with respect to the average expression level in synaptoneurosomes prepared from age-matched, mock-infected control mice. Data was then transformed to produce log 2 values and compared using a two-tailed t-test.
RT-PCR Validation
Select miRNAs were further validated using individual TaqMan miRNA Assays (Life Technologies). For miRNA reverse transcription reaction, the TaqMan miRNA Reverse Transcription Kit (Life Technologies) was used and for the PCR reaction, the TaqMan Universal PCR Master Mix 2×, No AmpErase UNG (Life Technologies) was used. Primers and probes used for the detection of miRNAs are listed in Supplemental data 1 and obtained from Life Technologies. Real-time PCR data were processed and analyzed using the comparative C T or ΔΔC T method (Cohen et al., 2011) . The ΔΔC T values were then expressed relative to U6, and the mean ± SD calculated from between 4 and 8 biological replicates.
Qualitative real-time PCR (qRT-PCR) was also performed using TaqMan assays (Applied Biosystems) and iTaq SybrGreen Supermix with ROX (Bio-Rad) for the detection of the non-coding RNA BC1 and U6.
Western blotting
Proteins were separated by SDS-PAGE and blotted onto a PVDF membrane. Non-specific binding was blocked with PBS plus 5% skim milk powder and 0.2% Tween 20. The following primary antibodies were used: rabbit anti-PSD95 (ab18258; Abcam), rabbit anti-Synapsin 1 (ab64581; Abcam), rabbit anti-GFAP (ab7260; Abcam) and mouse anti-α-tubulin (T9026; Sigma). The primary antibodies were recognized by horseradish peroxidase (HRP)-conjugated goat anti-rabbit antibody (P0448; DakoCytomation) at 1:500 dilutions. Secondary antibodies were detected by chemiluminescence using the SuperSignal West Pico Chemiluminescent Substrate system (Thermo Scientific). Sizes of resolved protein bands were determined using Novex Sharp Pre-Stained Protein Standard (LC5800; Life Technologies) and MagicMark XP Western Protein Standard (LC5603; Life Technologies).
Transmission electron microscopy
Freshly prepared synaptoneurosomes were fixed with EM fixative solution (4% paraformaldehyde, 5% glutaraldehyde in 0.1 M sodium ⁎ PFB = preclinical forebrain (prepared at 105 dpi), PH = preclinical hippocampal (prepared at 105 dpi), CFB = clinical forebrain (prepared at 167 dpi).
cacodylate and 3.4 mM calcium chloride, pH 7.2) and cut into 80 nm thick sections. Standard images were obtained using a CCD camera attached to the TEM. Representative synaptoneurosome preparations contained numerous intact synaptoneurosomes with a post-synaptic density, intact mitochondrion, and well preserved pre-synaptic vesicles.
The lightest subfraction contained primarily empty multi-lamellate myelin, as expected. Smaller cytoplasm containing membrane particles were also seen occasionally, along with some mitochondria trapped within the myelin fragments. The pellet was primarily enriched in mitochondria ( Supplementary Fig. 1) . Fig. 4 . Ingenuity Pathway Analysis illustrating the members of the synaptoneurosome proteome that are potentially direct targets of miRNAs altered in abundance in the synaptoneurosome during (A) early, and (B) clinical stages of prion disease by bioinformatics prediction analysis using the DIANA-mirPath v2.0 online tool. The intensity of "fill" is representative of the number of predicted target sites for altered miRNAs within the 3′ UTRs of genes encoding synaptoneurosomal proteins where no fill indicates no sites located, up to 8 sites (darkest fill).
Proteomic profiling by LC/MS and data analysis
100 mg of total protein was acetone-precipitated overnight at −20°C , followed by trypsin digestion. Briefly, trypsin digestion of the protein samples was performed using the Filter-Aided Sample Preparation method as described by Rodriguez-Lebron et al. (2013) with modifications by Michael Carpenter (personal communications). Samples were treated with 2% SDS and reduced with DTT, transferred to a Nanosep 10 K omega cartridge filter (Pall Life Sciences) and washed with 8 M urea in 50 mM HEPES, pH 8.0. The protein was then alkylated with iodoacetamide, treated with benzonase, and digested overnight with trypsin at 37°C.
LC separation was done using a Thermo Scientific Ultimate 3000 HPLC system and Michrom Magic C18 spray tip 15 cm × 75 μm i.d. column (Auburn, CA). Gradient elution was performed from 2 to 30% ACN in 0.1% formic acid over 100 min at a flow rate of 450 nL/min. The samples were analyzed with a Thermo Scientific Orbitrap Elite hybrid mass spectrometer. Two sets of triplicate runs were performed using MS resolution setting of 60 000 and 120 000 at m/z 400 in a top 10 CID data-dependent mode. MS spectrum was collected from 400 to 1600 m/z with an AGC target of 1e6 with a maximum injection time of 150 ms and an average of 1 microscan. For MS/MS precursors were fragmented using CID with normalized collision energy (NCE) of 30%. MSn target was set to 3e 4 with a maximum injection time of 300 ms with an average of 1 microscan. Dynamic exclusion was set to 180 s. Raw data files were searched using Thermo Scientific Proteome Discoverer software version 1.3 with Mascot v. 2.3 (Matrix Sciences) and SEQUEST search engines. For Mascot the NCBI database was used with taxonomy of Mus musculus. For SEQUEST Mus_musculus_Uniprot (taxonomy 10,090) database was used. Peptide validator node was set to a false discovery rate of 1% and proteins that were identified were based on this 1% FDR criterion. Peptide searches were performed using a 20 ppm precursor tolerance and 0.8 Da MS/MS tolerance, while allowing up to two missed cleavage. For peptide searches, carbamidomethylation of cysteine residues was set as static modification. Deamination on asparagine and glutamine, phosphorylation on serine and threonine and oxidation on methylation were set as dynamic modifications.
Functional analysis and miRNA target prediction
The Ingenuity Pathway Analysis (IPA) online tool (Qiagen, http:// www.ingenuity.com) was used to annotate the proteins that were identified by mass spectrometry in the synaptoneurosome fraction. A data set containing SwissProt accession numbers was uploaded and each was annotated with its corresponding gene symbol. Canonical pathways analysis identified the pathways from the IPA library of canonical pathways that were most significant in the data set. The significance of the association between the data set and the canonical pathway shown in Supplementary Table 4 is a Fisher's exact test calculated p-value corrected using the Benjamini and Hochberg Multiple Testing Method. The Path Designer function of IPA was used to generate a network of synaptoneurosomal proteins that correspond to Ingenuity gene identifiers with documented interactions within the Ingenuity Pathways Knowledge Base, and that are predicted targets of miRNAs altered in abundance in synaptoneurosomal fractions at preclinical and clinical time-points during prion disease. Shading was added based on the number of predicted target sites for these miRNAs within the 3′ UTRs of these genes.
DIANA-miRPath v2.0 (http://www.microrna.gr/miRPathv2) was applied to analyze the main functions of synaptoneurosomal miRNAs (Paraskevopoulou et al., 2013; Reczko et al., 2012) . MiRNA and pathway-related information was obtained from miRBase and the KEGG resource, respectively. A one-tailed Fisher's exact test was used to identify the enriched KEGG pathways with targets of specific miRNAs, and the Benjamini and Hochberg false discovery rate (FDR) was calculated to correct the p-value. Enrichment provides a measure of the significance of the function; as the enrichment increases, the corresponding function is more significant.
Discussion
In this study, we found that miRNAs are altered in abundance in synaptoneurosomes isolated from forebrain and hippocampus tissues of mice infected with the RML strain of scrapie. These changes are apparent at 105 dpi (preclinical disease) and by terminal stages of disease the number of altered miRNAs increases considerably and includes many that have previously been associated with prion infection in other studies. This is the first study to identify changes in the levels of specific miRNAs within a synaptoneurosome fraction during the progression of prion disease. It is becoming clear that miRNA mediated post-transcriptional regulation is important for orchestrating synaptic plasticity. Every neuron has between 10 3 and 10 4 synapses and is able to modify each synapse independently based on interaction with its cellular and extracellular environment. Substantial evidence points to regulation of local protein translation as a strong component of synaptic development and plasticity, potentially mediated by miRNAs enriched within synaptodendritic compartments (Lugli et al., 2008) . Therefore, disease-related miRNAs may well be pivotal modulators of the synaptic and cytoskeletal alterations that occur concomitantly with the replication of infectious prions and the alterations in cognition that accompany neurodegeneration. Overall, our data revealed the dynamic modulation of miRNAs between the preclinical and terminal stages of disease at which we sampled miRNA abundance within synaptoneurosomes from forebrain tissue samples. During preclinical disease, a small number of miRNAs were significantly increased. These were miR-136-5p, miR-376a-3p, miR-345-3p, miR-361-5p, miR-212-3p and miR-124a-3p. Of these miR-136-5p and miR-376a-3p were also increased in synaptoneurosomes from infected hippocampal tissues indicating some commonalities between affected neurons in different parts of the brain. Furthermore, a greater number of miRNAs were altered in infected hippocampal synaptoneurosomes than those isolated from forebrains, although we could not apply the same stringent statistics due to the requirement to pool individual hippocampi. Given that in previous work we identified miRNA dysregulation specifically in hippocampal CA1 neurons throughout the disease, we were interested to correlate our previous findings with the alterations in hippocampal synaptoneurosome preparations. However, we did not find any overlap with the miRNAs that we previously identified as dysregulated in hippocampal CA1 neurons, although miR-124-3p was similarly increased in preclinical forebrain derived synaptoneurosomes. This was perhaps at first surprising, however the two studies were sampling two spatially distinct pools of miRNAs. In the previous study, miRNA abundance within the microdissected cell bodies including the nucleus was sampled, suggesting altered transcription and/or processing of these miRNAs in the cytoplasm (Majer et al., 2012) . In the isolated synaptoneurosomes used in this study a number of other factors are at play and may explain variation in abundance of miRNAs during disease. One of these factors may be a general shift of miRNAs from the synaptoneurosome to the nuclear fraction, a phenomenon that has been described following pilocarpine induced status epilepticus (Risbud and Porter, 2013) , which could precede a loss of synapses although this has not yet been studied in relation to prion disease or any other neurodegenerative condition.
Other possible ways for miRNAs to be independently regulated in the synaptodendritic compartment is via their differential transport along the axon as it is known that a subset of miRNAs are particularly enriched at the synapse and have high synapse/nuclear abundance ratios (Doyle and Kiebler, 2011) . Increased transcription of miRNAs may also not be reflected in increased abundance within the synaptodendritic compartment as increased transport and utilization at the synapse may mask this by maintaining the same absolute amounts of mature miRNAs in isolated synaptoneurosomes. Conversely, miRNAs already present at the synapse may be processed locally during disease which would translate into the detection of increased abundance of the mature form within the synaptoneurosomes isolated from infected tissue. Other factors, such as alterations in the rate of degradation of miRNAs, which can have half-lives varying from minutes to weeks may account for altered detection of differential abundance between cell bodies and synaptodendritic compartments (Lugli et al., 2008; Bail et al., 2010) . Future targeted studies are required to measure processing, subcellular targeting and degradation of disease-related miRNAs.
MiR-124-3p was, however, upregulated in the previous study of miRNA expression in hippocampal CA1 neuronal cell bodies during preclinical stages of prion disease and also in the forebrain synaptoneurosomes. Of note, we also found miR-132-3p to be upregulated in the CA1 study and this miRNA is clustered with miR-212-3p that was altered in synaptoneurosomes. Both of these miRNAs are known to play roles in the regulation of neuronal morphology. MiR-124-3p targets Ephrin B, which functions in regulating cytoskeletal dynamics (Arvanitis et al., 2010) and its overexpression leads to increased neurite outgrowth by mediating GTPase Rho kinases (Maiorano and Mallamaci, 2009; Gu et al., 2014) . Transcription of the miR-212/132 cluster is induced by BDNF-mediated activation of the ERK1/2 pathway that leads to the activation of the transcription factor CREB; a transcription factor that we previously showed to be activated in hippocampal neurons during preclinical prion disease. Expression of miR-132-3p also promotes neurite outgrowth as deletion of the locus results in decreased spine density, dendrite length and arborization (Magill et al., 2010) . Although by the terminal stages of disease, dendritic spine and synapse loss is clearly evident in prion disease, as in other neurodegenerative diseases, at early stages of disease evidence suggests that increased spine remodeling occurs which involves breaking and reforming neuronal connections. We believe this explains our findings that during preclinical disease some miRNAs, as well as genes, that promote neurite outgrowth are induced transiently. Indeed, in the study recently published by Campeau et al. (2013) , an early short-lived increase in dendritic spine density was observed following prion infection of organotypic mouse cerebellar cultures, perhaps mimicking those suggested by miRNA and mRNA expression determined in our studies.
Synaptoneurosome miRNAs isolated from infected mice during terminal stages contained increased abundance of numerous miRNAs previously identified in prion disease. These included miR-146a-5p, miR-142-3p, miR-143-3p, miR-145a-5p, miR-451a, let-7b-5p, miR-320-3p and miR-150-5p all identified in previous studies (Majer et al., 2012; Saba et al., 2008; Montag et al., 2009 Montag et al., , 2012 . Also evident was an increase, albeit small, of miR-136-5p and miR-376a-3p, which were induced at preclinical disease in both forebrain and hippocampus synaptoneurosomes, as well as a small decrease in miR-129-2-3p and miR-361-5p. The consistency of detection of many of the same miRNAs across different experiments, sample types and time-points was notable.
MiR-146a-5p in particular has been consistently found to be upregulated in brain tissues from animal models and individuals suffering from various neurodegenerative conditions including prion disease and AD. In this study, we confirmed that this miRNA was increased between 4 and 7 fold in the synaptoneurosomes of prion infected mice by qRT-PCR. MiR-146-5p is known to be induced by TLR signaling in glial cells (Saba et al., 2012b; Lukiw et al., 2011; Iyer et al., 2012) and therefore we determined whether the synaptoneurosome preparation progressively included increasing amounts of material of glial origin. Using Western blots we showed that the levels of astrocyte specific marker GFAP were low and equivalent between control and infected synaptoneurosome preparations collected at either the preclinical and clinical disease.
We and others have also profiled miRNAs that are especially enriched in microglia, of which miR-342-3p, miR-20a/b, miR-155-5p. miR-221-3p/222-3p, miR-25, miR-125b-5p, miR-142-3p and miR146a-5p are major examples (Butovsky et al., 2014) . Other than miR146a-5p and miR-142-3p and a slight increase in miR-20a we did not find any of these to increase in abundance in the synaptoneurosome preparations collected at clinical disease. We concluded that although it is possible that increased miR-146a-5p and miR-142-3p were of microglial origin we think that alterations in abundance of miRNAs expressed by neurons has the largest contribution to the complement of miRNAs assayed in the synaptoneurosome preparation. We and others have found miR-146a-5p to be expressed in neurons of the hippocampus in vivo by in situ hybridization and in cultured hippocampal neurons by next generation sequencing and other methods (Zovoilis et al., 2011) . In fact, although most manuscripts describe the role of miR-146a-5p in immune cells, one interesting study describes how miR-146a-5p regulates dendritic microtubule-associated protein 1B (MAP1B). Here, it appears to modulate synaptic plasticity and suggests enrichment in the synaptodendritic compartment (Chen and Shen, 2013) . Upregulation of miR-146a-5p was implicated in synaptic dysfunction and loss by reduction in MAP1B, a protein required for dendritic spine development. Indeed, in MAP1B deficient mice, a decrease in the density of mature dendritic spines is evident (Tortosa et al., 2011) . Modulation of miR-146a-5p may therefore have a twofold effect in disease; to increase the host immune response to target misfolded protein aggregates and to increase dendritic MAP1B protein thus altering synaptic transmission.
Of the other miRNAs that are increased in abundance during clinical disease miR-142-3p has been reported to be induced following traumatic brain injury (Sun et al., 2014) and in multiple sclerosis and neuroAIDs where it has been shown to be a regulator of neurotransmission (Gandhi et al., 2013; Chaudhuri et al., 2013; Noorbakhsh et al., 2010) . Although also implicated to a large extent in the literature in innate and adaptive immune related roles, increased miR-150-5p has also been implicated in spinocerebellar ataxia type 1, a dominantly inherited neurodegenerative disorder caused by polyglutamine repeat expansions in Ataxin-1, as has miR-143-3p (Rodriguez- Lebron et al., 2013) . A further interesting possibility for the origin of increased miR-142-3p, miR-150-5p as well as miR-146a-5p, is deregulation within synaptic mitochondria. A recent study by Wang et al. showed that these three miRNAs are enriched in mitochondria isolated from hippocampal neurons relative to the cytoplasmic miRNA complement (Wang et al., 2015) The role of mitochondria in brain injury has been highlighted and mitochondrial dysfunction in prion disease is potentially a new avenue for exploration.
MiR-451a is a regulator of oxidative stress which is also potentially important in the neurodegenerative process and has been found to be particularly responsive to hypothermia, which has a profound effect on structural plasticity (Truettner et al., 2011) . The intense decrease in members of the miR-200 family (miR-200a-3p, miR-200b-3p, miR200c-3p, miR-141-3p, and miR-429-3p ) and the miR-182 cluster (miR-182-5p and miR-183-5p) of related miRNAs has been recognized in conditions such as hibernation in which dendritic spine densities are known to be decreased (Lee et al., 2012) and similarly following rabies infection. This group of miRNAs are also reduced in West Nile virus infection (Kumar and Nerurkar, 2014) , as well as in ischemia and mental illness (Lee et al., 2010; Kohen et al., 2014) . Evidence therefore suggests that this miRNA family possess host factors that can affect dendritic spine and synapse morphologies and function, and are particularly responsive to environmental stressors, injury or disease.
Conclusion
Our identification of miRNAs that alter in abundance within synaptoneurosomes is the first step to understanding the complex miRNA-mediated molecular interplay that undoubtedly underlies the development of disease and related neuropathology. Further studies evaluating miRNA deregulation at the synapse by directed manipulation of their expression in prion models are required to unravel their role in pathology. Additionally, identification of their targets will highlight those important synaptic proteins that require complex fine-tuning to precisely regulate their levels. Such proteins may well be important in the maintenance of healthy synaptic homeostasis and may themselves, and the pathways in which they are involved, represent new avenues for the development of therapeutics to promote healthy neuronal function.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.mcn.2015.12.001.
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